Uses of pharmacovigilance databases: An overview
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Over the past decades, assessment of drug safety and of their benefits harms balance has been profoundly modified by the availability of large databases and computerized automated statistical approaches. Improvement of digital data storage capacity has been applied to pharmacovigilance reports. VigiBase, the international pharmacovigilance database, is now aggregating over 21 million individual case safety reports in 2020. Identification and investigation of drug safety signals - concerning notably rare and unknown adverse drug reactions - is one of the major tasks in pharmacovigilance that can be amplified by automated signal detection. Several quantitative statistical methods exist, each with its own strengths and limits. Integrating signal detection, pharmacovigilance databases can be used for a wide variety of retrospective observational studies illustrated here by concrete examples. Confirming these signals by orthogonal validation using pre-clinical platforms and prospective trials is helpful. Pharmacovigilance databases represent a considerable source of information. However, the quality of signal detection and of pharmacoepidemiology studies in the field of adverse drug reaction closely depends on the quality of the individual data recorded.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Self-citationSalem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271
Self-citationIncreased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
Self-citationCardiovascular toxicities associated with immune checkpoint inhibitors
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508
Cited by
Gougis, P., Jochum, F., Abbar, B., Dumas, E., Bihan, K., Lebrun-Vignes, B., Moslehi, J., Spano, J.-P., Laas, E., Hotton, J., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102536 · Cited by 161
“7 Pharmacovigilance analysis allow for signal detection and generate hypothesis which need to be replicated ideally by prospective or translational mechanistic studies.”
BackgroundSelf-citationThymus alterations and susceptibility to immune checkpoint inhibitor myocarditis
Fenioux, C., Abbar, B., Boussouar, S., Bretagne, M., Power, J. R., Moslehi, J. J., Gougis, P., Amelin, D., Dechartres, A., Lehmann, L. H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02591-2 · Cited by 83
Self-citation
Metadata
- Authors
- Bihan, K., Lebrun-Vignes, B., Funck-Brentano, C., & Salem, J.-E.
- Venue
- Therapies
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 75
- Issue
- 6
- Pages
- 591-598
- ISSN
- 0040-5957 (ISSN-L)
- OpenAlex
- W3007610090
- Cited by
- 170
- References
- 4
- FWCI
- 40.35
- Type
- journal article
- Language
- fr
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Uses of pharmacovigilance databases: An overview. https://app.cochat.ai/papers/10.1016/j.therap.2020.02.022
- The paper
- Bihan, K., Lebrun-Vignes, B., Funck-Brentano, C., & Salem, J.-E. (2020). Uses of pharmacovigilance databases: An overview. Therapies. https://doi.org/10.1016/j.therap.2020.02.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.